Datma Launches Federated Biomarker Explorer, Offering Free Access to Empower Pharmaceutical Data Validation
NEW YORK, NY – July 9, 2025 – Datma, a leader in real-world data (RWD) solutions, today announced the launch of its innovative Federated Biomarker Explorer. This groundbreaking platform is now available with free access, designed to assist pharmaceutical companies in efficiently validating their real-world data coverage for critical biomarkers.
The Federated Biomarker Explorer addresses a significant challenge faced by the pharmaceutical industry: the need for comprehensive and reliable real-world data to support research, drug development, and regulatory submissions. Identifying and validating the presence and characteristics of specific biomarkers within vast and diverse datasets can be a complex and time-consuming process. Datma’s new platform aims to streamline this workflow, making it more accessible and efficient for life sciences organizations.
By leveraging federated learning technology, the Federated Biomarker Explorer allows pharmaceutical researchers to query multiple, disparate data sources without the need to centralize sensitive patient information. This approach inherently enhances data privacy and security, a paramount concern in healthcare research. Instead of moving data, the platform enables the execution of analytical models across distributed datasets, returning insights and coverage statistics directly to the user.
“We are thrilled to introduce the Federated Biomarker Explorer and provide free access to the pharmaceutical community,” said [Name and Title of Datma spokesperson, if available from the original article, otherwise generalize or omit]. “Our goal is to democratize access to powerful data validation tools. By enabling companies to easily assess their RWD coverage for essential biomarkers, we are helping to accelerate the understanding of disease, the development of new therapies, and ultimately, improve patient outcomes.”
The platform offers a user-friendly interface where researchers can define specific biomarkers of interest and then execute federated queries against a network of data custodians. The output provides crucial information regarding the availability and characteristics of the target biomarkers across these sources, allowing for informed decisions about data utility and potential gaps.
The free access model is a testament to Datma’s commitment to fostering innovation and collaboration within the life sciences sector. This initiative is expected to significantly lower the barrier to entry for companies looking to harness the power of real-world data for biomarker discovery and validation.
Datma’s Federated Biomarker Explorer represents a significant step forward in how the pharmaceutical industry interacts with and validates real-world data. Its innovative approach to privacy-preserving data analysis and its commitment to accessibility are poised to drive greater efficiency and deeper insights in the pursuit of groundbreaking medical advancements.
About Datma Datma is a leading provider of real-world data solutions, dedicated to transforming how life sciences organizations leverage data for research and development. Through its advanced federated learning technologies, Datma empowers clients to access and analyze valuable health information while prioritizing data privacy and security.
Contact: [Insert Press Contact Information Here, if available from the original article]
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Business Technology published ‘datma Launches Federated Biomarker Explorer with Free Access to Help Pharma Validate Real-World Data Coverage’ at 2025-07-09 12:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.